Helmut Bender

Manufacturer’s reply to letter by Seed and colleagues

Seed and colleagues suggest that the excipient benzalkonium chloride in the Respimat mist inhaler might partly explain the differences seen between placebo and the Respimat inhaler.1 The hypothesis is unfounded for three reasons. Firstly, the placebo in clinical trials with tiotropium Respimat was identical to the active treatment except for the lack of the active chemical entity. …